---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-002562"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2021-11-01T23:59:59+00:00"
generated_at: "2026-06-28T15:49:04.881666+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass reports CTX-009 Phase 2a ORR 29% in BTC; proposes public offering and Nasdaq uplist

## Summary
- CTX-009 Phase 2a in biliary tract cancer met criteria to advance; 5 partial responses in 17 patients (ORR 29%), 100% clinical benefit rate.
- Compass plans to submit US IND this quarter, initiate Phase 2 study in Q2 2022.
- Preliminary cash $25.5M as of Sep 30, 2021; proposes underwritten public offering of common stock plus 15% option for underwriters.
- Common stock approved for Nasdaq Capital Market listing under symbol CMPX, subject to offering pricing.

## SEC filing metadata
- accession: 0000950170-21-002562
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2021-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/0000950170-21-002562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/cmpx-20211101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-002562
- JSON: https://secwatch.observer/filing/0000950170-21-002562.json
- Plain text: https://secwatch.observer/filing/0000950170-21-002562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.